Fragile X syndrome (FXS) is the most common, monogenetic cause of intellectual disability and autism-spectrum disorders. Although there is no effective therapy, greater understanding of disturbed neuronal pathways has introduced options for targeted therapy. But whereas many FXS phenotypes were improved in preclinical studies with drugs targeting these pathways in the FXS mouse model, attempts to translate these animal-model success stories into treatment of patients in clinical trials have been extremely disappointing. Complicating factors, particularly in animal studies, include mouse inbred strains, variability in functional studies between laboratories, publication bias and lack of reliable and objective primary outcome measures in both mice and patients. Possibly most important, however, is one factor that has been little explored: the complexity of the molecular imbalance in FXS and the need to simultaneously target several different disturbed pathways and different cellular compartments. New, well-conceived animal studies should generate more productive approaches in the quest for targeted therapy for FXS.

Additional Metadata
Keywords FMR1
Persistent URL dx.doi.org/10.1517/14728222.2015.1079176, hdl.handle.net/1765/86422
Journal Expert Opinion On Therapeutic Targets
Citation
Zeidler, S, Hukema, R.K, & Willemsen, R. (2015). The quest for targeted therapy in fragile X syndrome. Expert Opinion On Therapeutic Targets (Vol. 19, pp. 1277–1281). doi:10.1517/14728222.2015.1079176